Join to View Full Profile
675 N St Clair StFloor 20Chicago, IL 60611
Phone+1 312-695-4360
Dr. Alshawa is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Anas Alshawa is a neurologist specializing in neurooncology, currently practicing in Chicago, IL. His education includes a residency and chief residency in neurology at the University of Arizona College of Medicine-Tucson and a neuro oncology fellowship at Northwestern Medicine, which he is presently undertaking. Dr. Alshawa serves as a Clinical Fellow at Northwestern Medicine and a Neurologist at Banner - University Medical Center Tucson. His research contributions include several publications in reputable journals, with topics focusing on treatments and responses in oncology, some of which have been well-cited, demonstrating their impact in the field.
Education & Training
Northwestern Medicine Neuro Oncology Fellowship, 2023 - 2025
University of Arizona College of Medicine-TucsonChief Residency, Neurology, 2022 - 2023- University of Arizona College of Medicine-TucsonResidency, Neurology, 2020 - 2023
University of Texas Rio Grande ValleyInternship, Transitional Year, 2018 - 2019
University of Aleppo Faculty of MedicineClass of 2014
Certifications & Licensure
IL State Medical License 2023 - 2026
IN State Medical License 2023 - 2025
AZ State Medical License 2022 - 2024
American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 4 citationsEffects of glutamine for prevention of radiation-induced esophagitis: a double-blind placebo-controlled trialAnas Alshawa, Alexandra P. Cadena, Bettzy Stephen, Akhila Reddy, Tito R. Mendoza
Investigational New Drugs. 2021-02-13 - 36 citationsEfficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study.Nazanin Majd, Steven G. Waguespack, Filip Janku, Siqing Fu, Marta Penas-Prado
Journal for Immunotherapy of Cancer. 2020-12-01 - 7 citationsDecrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumorsCoya Tapia, Phyu P. Aung, Sinchita Roy-Chowdhuri, Mingxuan Xu, Fengying Ouyang
Journal for Immunotherapy of Cancer. 2020-04-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
